Compass Pathways expected to complete COMP360 new drug application within 2 weeks
CMPS Compass Pathways Plc ADR
$9.25 +0.76%
View chart & analysis → 
- 1Compass Pathways expects to complete the new drug application for COMP360 within 2 weeks.
- 2Compass Pathways' third-quarter diluted net loss per share of $0.31 was less than the analyst estimate of $0.41.
- 3CEO Kabir Naehr disclosed preparations for a potential launch in the first half of 2027.
So what's the key point?
Compass Pathways is expected to apply for new drug approval within 2 weeks. The company reported a smaller loss than experts had predicted.
Source Stocktwits +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.